What is AM-Pharma?
Headquartered in Utrecht, the Netherlands, AM-Pharma was founded in 2001 and specializes in sepsis-associated acute kidney injury. The company's focus on this severe condition positions it within the critical care and pharmaceutical development sector. Its late-stage clinical development and manufacturing capabilities suggest a mature operational framework aimed at bringing vital treatments to market.
How much funding has AM-Pharma raised?
AM-Pharma has raised a total of $325.2M across 6 funding rounds:
Series A
$781K
Series C
$3M
Series D
$34.5M
Series E
$14.4M
Private Equity
$87.5M
Series F
$185M
Series A (2001): $781K with participation from Biopartners Capital
Series C (2007): $3.1M led by Forbion Capital and Inventages
Series D (2011): $34.5M supported by Ysios Capital Partners, Inventages, Kurma Partners, BB Biotech Ventures, Idinvest Partners, and Forbion
Series E (2014): $14.4M featuring Ysios Capital, Kuma Biofund, Gilde Healthcare, BB Biotech Ventures, IDInvest Partners, and AbbVie
Private Equity (2015): $87.5M backed by Pfizer
Series F (2020): $185M with participation from ID Invest Partners, Kurma Partners, Life Sciences Partners, BB Pureos Bioventures, Gilde Healthcare, Andera Partners, Cowen Healthcare Investments, Ysios Capital, and European Investment Bank
Key Investors in AM-Pharma
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe. They specialize in investing at various maturity stages, from the inception of companies to capital expansion. With a strong network of partners, Kurma transforms disruptive scientific discoveries into advanced medical solutions, focusing on severe diseases with high unmet medical needs.
Life Sciences Partners
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over €1.4 billion across three fund strategies: Venture & Growth in Healthcare, Private Equity in Healthcare, and Private Equity in Climate Solutions. The firm focuses on investing in businesses that enable better care at lower costs and address planetary challenges through energy transition, biodiversity, and waste management.
What's next for AM-Pharma?
The recent major strategic investment indicates a pivotal moment for AM-Pharma, likely signaling an acceleration of its late-stage clinical trials, expansion of manufacturing capacity, or preparation for commercial launch. This substantial backing from prominent investors suggests confidence in the company's therapeutic pipeline and its potential to address significant unmet medical needs in acute kidney injury and sepsis.
See full AM-Pharma company page
